Valuation: Bicycle Therapeutics plc

Market Cap 296M 259M 239M 223M 420M 27.99B 428M 2.87B 1.11B 13.81B 1.11B 1.09B 48.11B P/E 2026 *
-1.82x
P/E 2027 * -2.02x
Enterprise Value -216M -189M -175M -163M -307M -20.42B -312M -2.09B -813M -10.08B -811M -793M -35.11B EV / Sales 2026 *
-11.8x
EV / Sales 2027 * -7.66x
Free-Float
6.21%
Yield 2026 *
-
Yield 2027 * -
1 day+2.17%
1 week+6.00%
1 month-9.59%
3 months-8.62%
6 months-40.11%
Current year-40.11%
1 week 3.92
Extreme 3.92
4.34
1 month 3.92
Extreme 3.92
4.5
Current year 3.92
Extreme 3.92
7.34
1 year 3.92
Extreme 3.92
9.18
3 years 3.92
Extreme 3.92
28.67
5 years 3.92
Extreme 3.92
62.08
10 years 3.92
Extreme 3.92
62.08
Manager TitleAgeSince
Chief Executive Officer 57 31/08/2015
Director of Finance/CFO 46 28/01/2026
Chief Tech/Sci/R&D Officer - 31/05/2025
Director TitleAgeSince
Director/Board Member 57 31/08/2015
Director/Board Member 63 16/03/2021
Director/Board Member 69 19/02/2024
Date Insider Type Main position Quantity % Market Cap.
04-01Sell

Chief Technology Officer

2,404 0.0063%
04-01Sell

Chief Financial Officer

901 0.0024%
04-01Sell

Chief Operating Officer

1,408 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
+2.17%+6.00%-38.99%-83.39% 290M
+3.31%-0.20%+72.71%+128.31% 55.78B
-1.32%+17.12%+79.02%+99.82% 55.66B
-1.28%+2.68%-12.60%-13.79% 23.84B
+1.79%+4.38%+5.94%+405.31% 22.7B
-1.93%+11.11%+34.89%-7.86% 18.5B
+4.45%+5.06%+36.50%-30.43% 16.12B
+0.24%+5.98%+23.45%+184.72% 13.64B
+0.14%+9.60%+33.31% - 12.95B
+1.83%+4.58%+77.42%+132.45% 12.16B
Average +0.94%+6.09%+31.17%+90.57% 23.16B
Weighted average by Cap. +0.80%+5.21%+48.37%+114.58%

Financials

2026 *2027 *
Net sales 18.24M 15.96M 14.73M 13.74M 25.9M 1.72B 26.36M 177M 68.61M 851M 68.51M 66.98M 2.96B 14.11M 12.35M 11.4M 10.64M 20.04M 1.33B 20.4M 137M 53.1M 658M 53.02M 51.84M 2.29B
Net income -154M -134M -124M -116M -218M -14.53B -222M -1.49B -578M -7.17B -577M -564M -24.98B -162M -142M -131M -122M -231M -15.35B -235M -1.57B -611M -7.57B -610M -596M -26.39B
Net Debt -512M -448M -414M -386M -727M -48.41B -740M -4.96B -1.93B -23.89B -1.92B -1.88B -83.22B -404M -354M -327M -305M -574M -38.21B -584M -3.92B -1.52B -18.86B -1.52B -1.48B -65.69B
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
30/06/26 US$4.240 +2.17% 428,207
29/06/26 US$4.150 +1.22% 783,600
26/06/26 US$4.100 +2.24% 843,360
25/06/26 US$4.010 +1.26% 504,336
24/06/26 US$3.960 -1.00% 401,757
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.240USD
Average target price
12.62USD
Spread / Average Target
+197.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock